Affymax weakness a buying opportunity, says RW Baird at RW Baird

theflyonthewall.com

Baird expects Affymax shares to recover over the next few months following another bullish survey from Omontys users which indicated robust demand, and improved perceptions and preference for the drug. Shares are Outperform rated with a $30 price target.

Rates

View Comments